PD-L1 表达在结直肠癌中的临床病理和预后意义：系统评价和荟萃分析。

Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis.

机构信息

The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.

Department of General Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.

出版信息

World J Surg Oncol. 2019 Jan 4;17(1):4. doi: 10.1186/s12957-018-1544-x.

DOI:10.1186/s12957-018-1544-x

PMID:30609938

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6320581/

Abstract

OBJECTIVE

To analyze the prognostic value of programmed death factor ligand 1 (PD-L1) in colorectal cancer.

METHODS

Electronic databases, such as PubMed, Web of Science, Embase, and Cochrane library, were searched to identify studies evaluating the PD-L1 expression and overall survival (OS) in these patients. Afterwards, the relevant data were extracted to perform the meta-analysis.

RESULTS

A total of 3481 patients were included in 10 studies. The combined hazard ratio (HR) was 1.22 (95%CI = 1.01-1.48, P = 0.04), indicating that high expression of PD-L1 was significantly correlated with poor prognosis of colorectal cancer. Apropos of clinicopathological features, the merged odds ratio (OR) exhibited that highly expressed PD-L1 was firmly related to lymphatic invasion (OR = 3.49, 95%CI = 1.54-7.90, P = 0.003) and advanced stage (OR = 1.77, 95%CI = 1.41-2.23, P < 0.00001), but not correlative with patients' gender, microsatellite instability, or tumor location.

CONCLUSION

The expression of PD-L1 can be utilized as an independent factor in judging the prognosis of colorectal cancer, and patients with advanced cancer or lymphatic invasion are more likely to express PD-L1. This conclusion may lay a theoretical foundation for the application of PD-1/PD-L1 immunoassay point inhibitors but still needs verifying by sizeable well-designed cohort studies.

摘要

目的

分析程序性死亡因子配体 1（PD-L1）在结直肠癌中的预后价值。

方法

检索电子数据库，如 PubMed、Web of Science、Embase 和 Cochrane 图书馆，以鉴定评估这些患者 PD-L1 表达与总生存期（OS）的研究。然后，提取相关数据进行荟萃分析。

结果

共纳入 10 项研究的 3481 例患者。合并的风险比（HR）为 1.22（95%CI=1.01-1.48，P=0.04），表明 PD-L1 高表达与结直肠癌预后不良显著相关。关于临床病理特征，合并的优势比（OR）表明，PD-L1 高表达与淋巴侵犯（OR=3.49，95%CI=1.54-7.90，P=0.003）和晚期（OR=1.77，95%CI=1.41-2.23，P<0.00001）显著相关，而与患者性别、微卫星不稳定性或肿瘤位置无关。